Health Care Affordability

Moriarty Discusses Health Care Leadership with U.S. News & World Report

Moriarty Discusses Health Care Leadership with U.S. News & World Report
Bottom of the article
03.21.19

At the 2019 World Economic Forum, Tom Moriarty, Chief Policy and External Affairs Officer, and General Counsel for CVS Health, sat down with Bill Holiber, President and CEO of U.S News & World Report, to discuss how leadership in the health care industry can drive meaningful solutions for patients.

The conversation first focused on the important role leaders can play in driving a transformative vision forward. Moriarty explained that leaders, particularly in health care, need to listen and engage at a very human level.

Emphasizing the importance of providing human interactions in health care, Moriarty outlined CVS Health’s commitment to delivering high-quality, community-based care. According to Moriarty, the democratization of care delivery – giving patients greater control of their health care decisions – provides an opportunity to help patients find the right care at the best possible cost.

As an example, Moriarty referenced the real-time benefits program, which improves transparency for patients and their prescribers by showing what patients will pay for a specific drug under their benefits plan and presenting up to five lower-cost, clinically appropriate alternatives. Moriarty described the potential for solutions like this to improve health care outcomes and reduce overall costs to the system, so that those savings can be reinvested in other societal priorities, like education and infrastructure.

For more information about CVS Health’s efforts to improve access to quality care across the nation, visit our Quality & Access information center and the CVS Health Impact Dashboard. To stay informed about the latest updates and innovations from CVS Health, register for content alerts and our bi-weekly health care newsletter.

Tom Moriarty and Bill Holiber talk at Davos.
Hide Media Contacts (Sidebar)
No
Article
Hide Share
Off
"Likes" Count
0

CVS Health Offers Patients Lowest Cash Price in the Market for Generic Epinephrine Auto-injector to Treat Allergic Reactions

Top of the article
01.12.17

Generic epinephrine auto-injector from Impax Laboratories available at CVS Pharmacy at cash price 80% lower than EpiPen®

WOONSOCKET, R.I., Jan. 12, 2017 /PRNewswire/ -- CVS Health (NYSE: CVS) today announced that a low-cost epinephrine auto-injector option, the authorized generic for Adrenaclick manufactured by Impax Laboratories (IPXL), is available at all CVS Pharmacy locations at a cash price of $109.99 for a two-pack. This compares to a cash price of $649.99 for EpiPen and $339.99 for the authorized generic for EpiPen.

"As a health care company focused on helping people on their path to better health, we recognized that there was an urgent need in the marketplace for a less expensive epinephrine auto-injector for patients with life-threatening allergies," said Helena Foulkes, President of CVS Pharmacy. Over the past year, nearly 150,000 people signed on to a petition asking for a lower cost epinephrine auto-injector option and millions more were active in social media searching for a solution.

"In order to address this challenge," Foulkes continued, "we have partnered with Impax to purchase their epinephrine auto-injector at a price that is lower than similar brand or authorized generic epinephrine auto-injectors. We are passing these savings along to our customers and patients, making this product available at all CVS Pharmacy locations at the lowest cash price in the market."

The price of $109.99 for the authorized generic of Adrenaclick two-pack applies to both insured and cash-paying patients without insurance. This solution will be particularly beneficial for those insured patients who have consumer-directed health plans and have not yet met their deductible for the plan year. Additional cost reductions for the generic Adrenaclick are available for qualifying patients who use the coupon program offered through Impax which provides a benefit of $100 per pack.

"We are thrilled to work with CVS Health to increase access to our low-cost generic Adrenaclick epinephrine auto-injector," said Douglas Boothe, President, Generics Division, Impax Laboratories. "Families need and deserve an affordable option to treat severe allergies."

"We're encouraged to see national efforts to make epinephrine auto-injectors more affordable and more available to Americans across the country," said Cary Sennett, MD, PhD, President and CEO of the Asthma and Allergy Foundation of America. "Partnerships that increase access to vital medications are key in helping those suffering from life-threatening allergies."

"Anaphylaxis is a rapid onset, life-threatening allergic reaction that requires immediate diagnosis and treatment. For these patients, having access to emergency epinephrine is a necessity. Making an affordable epinephrine auto-injector device accessible to patients will ensure patients have the medicine they need, when they need it," said Todd M Listwa, MD, FACEP, Novant Health.

The authorized generic of Adrenaclick is a Food and Drug Administration (FDA) approved device with the same active ingredient as other epinephrine auto-injector devices. The American Academy of Allergy, Asthma and Immunology (AAAAI) includes generic Adrenaclick among therapeutic options in an anaphylaxis emergency action plan.https://www.aaaai.org/Aaaai/media/MediaLibrary/PDF%20Documents/Libraries/Anaphylaxis-Emergency-Action-Plan.pdf

About CVS Health

CVS Health is a pharmacy innovation company helping people on their path to better health. Through its more than 9,600 retail pharmacies, more than 1,100 walk-in medical clinics, a leading pharmacy benefits manager with more than 80 million plan members, a dedicated senior pharmacy care business serving more than one million patients per year, and expanding specialty pharmacy services, the Company enables people, businesses and communities to manage health in more affordable and effective ways. This unique integrated model increases access to quality care, delivers better health outcomes and lowers overall health care costs. Find more information about how CVS Health is shaping the future of health at https://www.cvshealth.com.

EpiPen is the registered trademark of Mylan Inc. Adrenaclick is the registered trademark of Lineage Therapeutics, Inc., which is a wholly-owned subsidiary of Impax Laboratories, Inc.

Media Contacts:

Erin Britt
(401) 770-9237
Erin.Britt@CVSHealth.com

Carolyn Castel
(401) 770-5717
Carolyn.Castel@CVSHealth.com

SOURCE CVS Health

Hide Media Contacts (Sidebar)
No
Press Release
"Likes" Count
0

CVS Health Details Programs and Pricing Transparency Solutions Addressing High Cost Drug Issue at AHIP National Policy Conference

Top of the article
03.08.18

Tom Moriarty, Chief Policy and External Affairs Officer, discusses programs that help consumers manage out-of-pocket drug costs and provide cost transparency across all points of care

Point of Sale rebate program, in place since 2013, helps 12 million plan members to reduce out-of-pocket costs

WOONSOCKET, R.I., March 8, 2018 /PRNewswire/ -- CVS Health (NYSE: CVS) Chief Policy and External Affairs Officer Tom Moriarty spoke to attendees at the AHIP National Policy Conference in Washington, DC today about ways the health care company is addressing the high cost of prescription drugs for payors and consumers. Moriarty highlighted a variety of approaches, including a new program that provides drug cost transparency for prescribers, pharmacists and patients. He also discussed the company's existing Point of Sale rebate offering which passes negotiated drug rebates directly to consumers when they purchase their medications.

"With more and more consumers in health plans with high deductibles, many are seeing the true cost of their medications for the first time, often at the pharmacy counter when they go to pick up their prescription," said Moriarty. "That is why we developed and introduced a system that provides true cost transparency by sharing member-specific drug cost information, formulary coverage and available lower-cost alternatives with doctors at the moment when they are writing the prescription."

Early results show that the vast majority of prescribers using this real-time benefits capability enabled through their electronic health record (EHR) have switched their patients' drug when it is not covered on their formulary or if there is a less expensive option available. In addition, this transparency empowers the physician, pharmacist and patient to have a more meaningful dialogue about appropriate medications and their costs, helping to identify opportunities for lower out-of-pocket costs for patients.

"Another way we help make prescription drugs more affordable for consumers is through Point of Sale rebates, which we have offered to our commercial clients since 2013," added Moriarty. "We currently cover nearly 12 million people under this option, by which the estimated value of negotiated rebates on branded drugs is passed along to the consumer when they get their prescription."

About CVS Health

CVS Health is a pharmacy innovation company helping people on their path to better health. Through its more than 9,800 retail locations, more than 1,100 walk-in medical clinics, a leading pharmacy benefits manager with more than 94 million plan members, a dedicated senior pharmacy care business serving more than one million patients per year, expanding specialty pharmacy services, and a leading stand-alone Medicare Part D prescription drug plan, the company enables people, businesses and communities to manage health in more affordable and effective ways. This unique integrated model increases access to quality care, delivers better health outcomes and lowers overall health care costs. Find more information about how CVS Health is shaping the future of health at www.cvshealth.com.

Contacts:

Christine Cramer
CVS Health
(401) 770-3317
christine.cramer@cvshealth.com  

Erin Britt
CVS Health
(401) 318-3962
erin.britt@cvshealth.com

SOURCE CVS Health

Hide Media Contacts (Sidebar)
No
Press Release
Hide Share
Off
"Likes" Count
0

CVS Health Kept Drug Price Growth Nearly Flat and Improved Medication Adherence for PBM Clients in 2017

Top of the article
04.05.18

PBM clients had lowest prescription drug trend in five years

Average member out-of-pocket costs declined and adherence improved in key categories such as diabetes, high blood pressure and high cholesterol

WOONSOCKET, R.I., April 5, 2018 /PRNewswire/ -- CVS Health (NYSE: CVS) today announced that, in 2017, the company kept drug price growth nearly flat for its pharmacy benefit management (PBM) clients, at a minimal 0.2 percent, despite manufacturer price inflation near 10 percent. Overall, the combination of this nearly flat drug price growth, with low drug utilization growth of 1.7 percent, reduced drug trend for commercial clients to 1.9 percent, the lowest level in five years. Out-of-pocket costs for members also declined, with three out of four members spending less than $100 out-of-pocket for their prescription medications, and nearly 90 percent of members spending less than $300, even as adherence improved to its highest level in seven years. In addition, 42 percent of CVS Health commercial PBM clients spent less on their pharmacy benefit plan in 2017 than they had in 2016.

"The health care landscape continues to evolve, but the cost of drugs remains a top concern for our clients and their members, who turn to us to ensure they are getting the most out of their pharmacy benefit plan," said Jon Roberts, executive vice president and chief operating officer, CVS Health. "At CVS Health, we always encourage the use of clinically appropriate therapeutic alternatives including generics, which can lower cost for payors and members, leverage competition within drug classes where applicable, and develop innovative strategies to keep prescriptions affordable. By lowering member costs, we are also helping to remove a key barrier to adherence. Members who are more adherent have better health outcomes and ultimately lower overall health care costs."

In 2017, growth in generic utilization played a major role in helping keep overall and member-specific costs low. In fact, the generic dispensing rate (GDR) for CVS Health PBM clients was above 86 percent. PBM strategies such as preventive drug lists with $0 copays for generics, as well as formulary strategies that promote the use of generics first, helped reduce costs for high utilization categories such as antihypertensives and cholesterol-reducing drugs. In addition, plan designs that promoted lower-cost options and targeted adherence interventions also helped increase the percentage of members who stayed on their therapy and were optimally adherent to their medications by as much as 1.8 percentage points in key categories such as diabetes, high blood pressure and high cholesterol.

Although manufacturer-driven price inflation for specialty drugs measured 8.3 percent in 2017, CVS Health was able to keep specialty drug cost growth at just 3.7 percent for clients. This was achieved through effective formulary strategies, indication- and outcomes-based contracting and cost-cap based rebates.

CVS Health also offers PBM clients a variety of formulary strategies, which are some of the most effective means of leveraging market competition. For clients aligned with the company's managed formularies, drug price actually declined by 0.1 percent, in 2017, as compared to the minimal 0.2 percent drug price growth seen across the commercial cohort. Also, despite greater utilization, clients aligned to the company's formulary approach also had lower per member per month costs. The company's formulary management approach includes careful, ongoing assessment of the marketplace, effective negotiations to be able to offer competitive pricing to clients, and the development of more targeted approaches, such as indication-based formularies, in which prices and rebates for a drug are negotiated based on its effectiveness to treat a specific diagnosis rather than at a therapy class level.

To further enhance affordability and price transparency, in late 2017, CVS Health introduced real-time benefits enabling prescribers to see the member-specific out-of-pocket costs of a prescribed medication as well as the costs of clinically appropriate alternatives in real-time allowing prescriber to make more informed decisions and offer members medication options that may be more affordable.

Prescription drug trend is the measure of growth in prescription spending per member per month. Trend calculations take into account the effects of drug price, drug utilization and the mix of branded versus generic drugs as well as the positive effect of negotiated rebates on overall trend. The 2017 trend performance is based on a cohort of CVS Health commercial PBM clients employers and health plans.

To learn more about the CVS Caremark 2017 drug trend, click here.

About CVS Health

CVS Health is a pharmacy innovation company helping people on their path to better health. Through its more than 9,800 retail locations, more than 1,100 walk-in medical clinics, a leading pharmacy benefits manager with more than 94 million plan members, a dedicated senior pharmacy care business serving more than one million patients per year, expanding specialty pharmacy services, and a leading stand-alone Medicare Part D prescription drug plan, the company enables people, businesses and communities to manage health in more affordable and effective ways. This unique integrated model increases access to quality care, delivers better health outcomes and lowers overall health care costs. Find more information about how CVS Health is shaping the future of health at https://www.cvshealth.com.

Media Contact:

Christine Cramer
CVS Health
(401) 770-3317
christine.cramer@cvshealth.com  

Investor Contact:

Mike McGuire
CVS Health
(401) 770-4050
michael.mcguire@cvshealth.com  

 

SOURCE CVS Health

Hide Media Contacts (Sidebar)
No
Press Release
Hide Share
Off
"Likes" Count
0

A Day in the Life of a MinuteClinic Nurse Practitioner

A Day in the Life of a MinuteClinic Nurse Practitioner
Bottom of the article
02.12.19

Convenience and affordability are two important factors that inform a patient’s decision when choosing a site of care. With more than 1,100 locations in 33 states and Washington D.C. and a majority of services costing less than $100, MinuteClinic is both a convenient and affordable option for patients looking for common health care services in their local community.

Administering those services seven days a week are more than 3,000 nurse practitioners and physician assistants who specialize in family health care and can diagnose, treat and write prescriptions for common illnesses.

Our MinuteClinic providers can treat more than 125 conditions in patients older than 18 months, including earaches, sprains and skin conditions. They also give common vaccinations and provide prevention and wellness services including screening and monitoring for diabetes, high blood pressure and high cholesterol, tuberculosis (TB) testing, travel health, contraceptive care, motion sickness prevention and smoking cessation.

And our MinuteClinic nurse practitioners and physician assistants go beyond direct care. They not only open and close the clinics and handle billing, they also follow up with patients and communicate - with permission - results to a patient’s primary care provider. The work they do every day directly impacts the lives of millions of patients and is one way we are able to fulfill our purpose of helping people on their path to better health.

Visit the MinuteClinic page to learn more about our clinical services. 

A MinuteClinic nurse practitioner examining a patient’s ear.
Hide Media Contacts (Sidebar)
No
Article
"Likes" Count
0

Helping Members Avoid Unnecessary ER Visits

Helping Members Avoid Unnecessary ER Visits
Bottom of the article
11.06.18

At an average total cost per visit of $1,900, the emergency department, or ER, is one of the most expensive places to receive medical care.https://www.beckershospitalreview.com/eds/cost-of-er-visits-increased-31-between-2012-16-5-findings.html Not surprisingly, consumer out-of-pocket costs are also high. According to one study, patients with upper respiratory infections personally paid an average of $377 per ER visit.https://www.bcbs.com/sites/default/files/file-attachments/health-of-america-report/BCBS.HealthOfAmericaReport.Retail.pdf

Despite these high costs, there were nearly 137 million ER visits in 2015.https://www.cdc.gov/nchs/fastats/emergency-department.html A sizable portion of these visits are for conditions that clearly merited emergent care — trauma, fractures, chest pain — but many others could be successfully treated at easier-to-access and more affordable sites of care. In fact, it’s estimated that 30 percent of ER visits could potentially be treated in walk-in clinics like MinuteClinic.https://www.bcbs.com/sites/default/files/file-attachments/health-of-america-report/BCBS.HealthOfAmericaReport.Retail.pdf

The emergency department is a critical component in our health care system, and crowding has become a concern among hospitals, policy makers, providers, and payors. Avoidable use among patients with low-acuity problems contributes to long ER wait times and suboptimal care. Avoidable visits cost the system $38 billion a year.http://wellness.totalaccessmedical.com/blog/the-consequences-of-emergency-department-overuse

Why People Choose the ER

In a survey, most ER users cited the severity of their medical problem as the primary reason they sought care in the emergency department. However, 7 percent cited lack of access to a primary care provider, and 12 percent went to the ER because their provider’s office was closed.https://www.cdc.gov/nchs/data/nhsr/nhsr090.pdf With extended hours and walk-in care, retail clinics are a convenient choice for these groups. Retail clinics are a particularly attractive option for younger people who may not have established a relationship with a primary care provider.

The Neighborhood Option for Care

Many of the concerns that bring people to a hospital emergency department can be effectively treated in walk-in medical clinics. Earaches, sprains, skin conditions such as rashes or poison ivy, sore throats and infections of the respiratory system or urinary tract can all be treated at MinuteClinic. In fact, MinuteClinic can treat more than 125 different conditions in patients above 18 months of age.

Helping plan members and plans avoid unnecessary ER visits remains a part of CVS Health’s vision for building a better, more affordable health care system. MinuteClinic, with 1,100 locations in 33 states and the District of Columbia, offers care seven days a week, including times when many physician offices are closed. Most services at MinuteClinic cost approximately $100. A visit to MinuteClinic — as opposed to an urgent care center or hospital emergency department — costs as much as 90 percent less.

Read the full article at CVS Health Payor Solutions.

For more information about CVS Health’s efforts to improve access to quality care across the nation, visit our Quality & Access information center and the CVS Health Impact Dashboard. To stay informed about the latest updates and innovations from CVS Health, register for content alerts and our bi-weekly health care newsletter.

Woman blowing her nose
Hide Media Contacts (Sidebar)
No
Article
Hide Share
Off
"Likes" Count
0

CVS Health Lauds New Research Showing that Limiting Pharmaceutical Detailing Can Impact Prescribing Behavior

Top of the article
05.02.17

Findings are an important recognition of the role of pharmaceutical companies in influencing prescribing behavior that could drive up health care costs

Overuse of brand name drugs resulted in $73 billion in costs to the U.S. health care system between 2010-2012

WOONSOCKET, R.I., May 2, 2017 /PRNewswire/ -- CVS Health (NYSE: CVS) today lauded findings from new research showing that policies limiting pharmaceutical sales activities at academic medical centers resulted in a modest, but significant change in prescribing behavior. The research, published today in an issue of the Journal of the American Medical Association (JAMA) focused on conflicts of interest in medicine, found that when these policies were implemented there was a decrease in prescribing of drugs detailed by pharmaceutical sales representatives and an increase in prescribing of non-detailed drugs, the majority of which (more than 95 percent) were generics. This research underscores the need for continued monitoring of pharmaceutical marketing practices and the ongoing adoption of programs and policies that increase the availability and utilization of generic drugs in the marketplace, as a way to help drive down overall drug spending.

"Physician visits from drug sales representatives help keep expensive brand name drugs top-of-mind for physicians, which can ultimately impact their prescribing behavior," said Troyen A. Brennan, M.D., Chief Medical Officer of CVS Health and a study co-author. "At a time when the cost of prescription drugs and pharmacy care is under increased scrutiny, this new data shows that policies to restrict pharmaceutical sales calls can lead to increased prescribing of equally effective, less expensive generic drugs."

Researchers at the UCLA Medical Center and Carnegie Mellon University compared prescribing practices of physicians at academic medical centers in five states before and after implementation of restrictive pharmaceutical detailing policies over a six-year period. De-identified pharmacy claims data was provided by CVS Health for eight drug classes used to treat common, chronic conditions for which lower-cost generics are available, including high blood pressure and high cholesterol. The study found that when more restrictive policies to limit on-site pharmaceutical marketing activity were adopted by the medical centers, there was a decrease in market share of 1.67 percentage points for brand name drugs previously detailed by pharmaceutical representatives and an increase in market share of lower cost, mostly generic, alternatives by 0.84 percentage points across the majority of drug classes.

"This research is instructive as we look at ways to help curb overall health care spending and points to a tremendous opportunity for increasing utilization of generic medicines as a measured approach to help control overall pharmacy spend," added Dr. Brennan. "In fact, when high cost brand name drugs are prescribed more often, research suggests that overall health care spending can rise exponentially, much of which is likely avoidable."

Clinically equivalent and often more cost effective than their brand name counterparts, generic drugs help control pharmacy spend and increase access to important therapies for patients who could be deterred by the high cost of some branded drugs. In fact, according to the Association for Accessible Medicines, the use of generic drugs produces annual savings in excess of $200 billion. Additionally, in a separate editorial also published in today's issue of JAMA, authors cite research showing that the overuse of high cost brand name medications resulted in about $73 billion in costs to the U.S. health care system between 2010-2012, about a third of which was paid for by patients.

Pharmacy benefit managers (PBMs), including CVS Caremark, the PBM of CVS Health, also help drive value for payors and patients with formularies that favor generic drugs. In fact, in 2016, generic drugs had the largest deflationary impact on CVS Caremark drug trend the year-over-year growth in prescription spending due to higher dispensing rates combined with lower overall inflation and falling prices for most generics. In addition, increasing drug competition by addressing the backlog of generic medicines awaiting FDA approval and promoting policies that do not delay market entry of generic drugs will help increase the number of lower cost generic drugs available in the marketplace.

About CVS Health

CVS Health is a pharmacy innovation company helping people on their path to better health. Through its nearly 9,700 retail locations, more than 1,100 walk-in medical clinics, a leading pharmacy benefits manager with nearly 90 million plan members, a dedicated senior pharmacy care business serving more than one million patients per year, expanding specialty pharmacy services, and a leading stand-alone Medicare Part D prescription drug plan, the company enables people, businesses and communities to manage health in more affordable and effective ways. This unique integrated model increases access to quality care, delivers better health outcomes and lowers overall health care costs. Find more information about how CVS Health is shaping the future of health at https://www.cvshealth.com.

Media Contacts:

Christine Cramer
CVS Health
(401) 770-3317
christine.cramer@cvshealth.com

Christina Beckerman
CVS Health
(401) 770-8868
christina.beckerman@cvshealth.com

SOURCE CVS Health

Hide Media Contacts (Sidebar)
No
Press Release
"Likes" Count
0

CVS Health Research Institute Provides More Evidence that Broader Prescription Drug Coverage Improves Health Outcomes

Top of the article
01.13.15

WOONSOCKET, R.I., Jan. 13, 2015 /PRNewswire/ --A new analysis by researchers at Brigham and Women's Hospital and the CVS Health (NYSE: CVS) Research Institute, published on-line first in the American Journal of Public Health, shows that enhanced prescription drug insurance can improve patient health outcomes and reduce use of other, often costly, health care services.

"This review confirms the central role that effective prescription drug insurance can play as policymakers seek mechanisms to reduce rising health care costs in the United States," said Troyen A. Brennan, M.D., Chief Medical Officer, CVS Health and a study author. "Our analysis indicates that while expanding insurance benefits may lead to initial cost increases, these costs should be offset by future reductions in spending associated with preventable patient morbidity and mortality."

The authors conducted a systematic review of 23 studies that investigated prescription drug insurance changes between 1990 and 2013 and reported on associated health care use and patient health outcomes. Patients with government-sponsored drug insurance were the primary population studied. Across the reviewed research studies, the authors observed a consistent link between drug insurance and improved patient health status. For example, when drug insurance programs were enhanced or expanded, more patients were able to afford important medications enabling them to access and adhere to prescription medicines for chronic conditions. This, in turn, decreased costly complications and overall health care use, including hospitalizations from unmanaged or under-managed conditions. Several studies also showed a negative impact on patient health outcomes when insurers placed burdensome caps on drug benefits.

"As we continue to work towards balancing cost and quality in the U.S. health care system, this analysis suggests that policymakers should consider strategies other than limiting drug insurance," said the study's lead author, Aaron S. Kesselheim, M.D. Associate Professor of Medicine at Harvard Medical School and faculty member in the Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital. "These could include strategies aimed at increasing the accessibility of essential prescription drugs, such as timely availability of generic alternatives and policies designed to improve medication adherence."

Many public and private insurers are taking steps to control rising health care costs. For example, some state Medicaid programs in recent years have enacted prescription drug restrictions by placing caps or limits on the number of prescriptions a patient can fill each month. The results of this systematic review of past studies suggests that restricting the availability of prescription drugs or prohibiting access could have collateral negative effects on patients' health and may not produce the expected cost-savings. They also suggest that economic calculations of Medicaid expansion have not taken into consideration the reduction in costs from the prevention of complications when millions of Americans previously without drug insurance are able to access important medicines to better manage chronic conditions.

The CVS Health Research Institute is focused on contributing to the body of scientific knowledge related to pharmacy and health care through research collaborations with external academic institutions, participation in federally-funded research, analysis and sharing of CVS Health data sources and coordination of pilot programs and initiatives. CVS Health Research Institute findings support a continuous quality improvement environment, which encourages product innovation and development to benefit CVS Health patients, clients and their members.

About CVS Health

CVS Health (NYSE: CVS) is a pharmacy innovation company helping people on their path to better health. Through our 7,800 retail pharmacies, more than 900 walk-in medical clinics, a leading pharmacy benefits manager with nearly 65 million plan members, and expanding specialty pharmacy services, we enable people, businesses and communities to manage health in more affordable, effective ways. This unique integrated model increases access to quality care, delivers better health outcomes and lowers overall health care costs. Find more information about how CVS Health is shaping the future of health at www.cvshealth.com.

Media Contacts

Erin Shields Britt
CVS Health
(401) 770-9237
erin.britt@cvscaremark.com

Christina Beckerman
CVS Health
(401) 770-8868
christina.beckerman@cvscaremark.com

Logo - http://photos.prnewswire.com/prnh/20140905/143585

To view the original version on PR Newswire, visit: http://www.prnewswire.com/news-releases/cvs-health-research-institute-provides-more-evidence-that-broader-prescription-drug-coverage-improves-health-outcomes-300019299.html

SOURCE CVS Health

Hide Media Contacts (Sidebar)
No
Press Release
"Likes" Count
0

CVS Health Announces New Clinical Affiliations with Leading Louisiana and Kansas Regional Health Systems

Top of the article
01.28.15

WOONSOCKET, R.I., Jan. 28, 2015 /PRNewswire/ --CVS Health (NYSE: CVS) announced today it has entered into new clinical affiliations with two leading regional health systems to enhance access to high-quality, affordable health care services for patients. The collaborating health systems include the LSU Healthcare Network in New Orleans, Louisiana and Shawnee Mission Health in Kansas. Through these clinical affiliations the patients served by these health systems will continue to have access to clinical support, medication counseling, chronic disease monitoring and wellness programs at CVS/pharmacy stores and MinuteClinic, the retail medical clinic division of CVS Health. In addition, CVS Health will provide critical prescription and visit information to the participating medical centers through the integration of secured electronic medical record (EMR) systems.

CVS/pharmacy currently has more than 7,800 retail pharmacy locations across the U.S. where CVS pharmacists provide counseling to patients to help them be adherent to their chronic disease medications. Of the total retail pharmacy locations, there are more than 900 MinuteClinic walk-in medical clinics available. MinuteClinic locations are open seven days a week, offering evening hours with no appointment necessary and most health insurance is accepted. The clinics are staffed by nurse practitioners and physician assistants who provide treatment for common family illnesses and administer wellness and prevention services, including health-condition monitoring for patients with chronic diseases.

"We look forward to working with these leading regional health systems to develop collaborative programs that improve patient outcomes, lower costs and help people on their path to better health," said Troyen A. Brennan, MD, Chief Medical Officer, CVS Health. "Through these clinical affiliations, we will also be integrating our electronic medical records and information systems to enable us to support patients with medication counseling and chronic disease monitoring."

The health care providers at the participating health systems will receive data on interventions conducted by CVS pharmacists to improve medication adherence for their patients. The affiliation also encourages collaboration between the health care providers and MinuteClinic providers to improve coordination of care for patients seen at MinuteClinic locations. Physicians affiliated with the participating health systems will collaborate with MinuteClinic nurse practitioners to work closely on joint clinical programs and care coordination activities. If more comprehensive care is needed, patients can follow up with their primary care provider and have access to the services at the medical center as appropriate. For those patients who do not have regular access to health care, MinuteClinic provides information to help patients in finding a primary care physician and a greater opportunity for continuity of health care services.

"Finding cost-effective ways to increase access to care continues to be important, especially in this era of health care reform, and we are pleased to work together with these health care providers to help coordinate comprehensive care for their patients," said Dr. Brennan. "Many patients rely on their local pharmacist for information and support regarding their prescription medications and these affiliations enable CVS pharmacists to help improve affiliated health care providers' patient health outcomes through better medication adherence. MinuteClinic also plays an important role by providing patients with timely, affordable and high-quality walk-in health care."

MinuteClinic, CVS/pharmacy and the participating health systems will begin to work toward integrating EMR systems to streamline communication. This integration will include the electronic sharing of messages and alerts from CVS/pharmacy to the health systems' physicians regarding potential medication non-adherence issues. In addition, MinuteClinic will electronically share medical histories and visit summaries with the patient's primary care physician when they are part of a health system affiliate and with the patient's consent. MinuteClinic will continue its standard practice of sending patient visit summaries to primary care providers who are not affiliated with one of these participating health systems via fax or mail, with patient consent.

The new clinical affiliations announced here bring the total number of health system and health care provider affiliations for CVS Health and MinuteClinic to 50 major health systems and health care providers across the country.

About CVS Health
CVS Health (NYSE: CVS) is a pharmacy innovation company helping people on their path to better health. Through our 7,800 retail pharmacies, more than 900 walk-in medical clinics, a leading pharmacy benefits manager with nearly 65 million plan members, and expanding specialty pharmacy services, we enable people, businesses and communities to manage health in more affordable, effective ways. This unique integrated model increases access to quality care, delivers better health outcomes and lowers overall health care costs. Find more information about how CVS Health is shaping the future of health at www.cvshealth.com.

Contact:
Christina Beckerman
CVS Health
(401) 770-8868
christina.beckerman@cvscaremark.com

Logo- http://photos.prnewswire.com/prnh/20140905/143585

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cvs-health-announces-new-clinical-affiliations-with-leading-louisiana-and-kansas-regional-health-systems-300026563.html

SOURCE CVS Health

Press Release
"Likes" Count
0

CVS Health Chief Medical Officer to Address National Business Group on Health on Value of Pharmacy Care in Evolving Health Care System

Top of the article
03.06.15

WOONSOCKET, R.I., March 6, 2015 /PRNewswire/ -- Troyen A. Brennan, M.D., M.P.H., Executive Vice President and Chief Medical Officer of CVS Health (NYSE: CVS), will speak before the National Business Group on Health in Washington, D.C. today. Brennan will outline ways pharmacy care can play a critical role in addressing health care cost and quality as the overall health care system faces increased stress. After making CVS/pharmacy the first national pharmacy chain to stop selling tobacco in support of the health and well-being of its patients and customers, CVS Health is moving aggressively to provide innovative new tools that can assist patients, providers and health plans improve medication adherence and ultimately improve health.

"Medication non-adherence can have a significant impact on patients' health outcomes and it costs the nation's health care system nearly $300 billion every year," Brennan said. "Sadly, one of the most significant challenges is patients often don't take their medications. They forget or they're confused, or they fail to understand why they should be taking them."

Brennan will highlight CVS Health's unique Pharmacy Advisor program designed to connect pharmacists, health care providers and health plans to deliver better care and value by stressing the importance of adherence to prescribed medications. He will also highlight innovations that are continuing to expand CVS Health's adherence program offerings, including packaging designed to help patients manage multiple medications and digital tools like texting and messaging patients about their medications.

"We can improve adherence and reduce gaps in care by connecting and integrating our interactions with patients, taking advantage of our ability to counsel patients at convenient touch points," Brennan said.

In his remarks, Brennan will also discuss how CVS Health is working to meet the needs of an evolving health care system. He will observe trends in health care costs and strategies to manage costs, Medicare and state health care budgets, employer-provided insurance and new modes of care delivery. He will examine how the post-recession climate and implementation of the Affordable Care Act are changing health care.

Brennan will also describe the critical role CVS/minuteclinic plays in the transforming health care system by providing accessible, quality, low-cost care. Through its clinics, CVS/minuteclinic can help patients with acute ailments or monitor chronic care for conditions like diabetes and hypertension, working directly with primary care doctors as part of the patient-centered medical home using electronic medical records.

"Connecting consumers into the health care system is our unique capability," Brennan has said. "Our MinuteClinics represent one way in which we can effectuate connectivity and integration in the health care system."

About CVS Health
CVS Health is a pharmacy innovation company helping people on their path to better health. Through our 7,800 retail pharmacies, 900 walk-in medical clinics, a leading pharmacy benefits manager with nearly 65 million plan members, and expanding specialty pharmacy services, we enable people, businesses and communities to manage health in more affordable, effective ways. This unique integrated model increases access to quality care, delivers better health outcomes and lowers overall health care costs.Find more information about how CVS Health is shaping the future of health at www.cvshealth.com.

Media Contacts:

Carolyn Castel
Corporate Communications
(401) 770-5717
Carolyn.Castel@CVSHealth.com

Erin Shields Britt
Corporate Communications
(401) 770-9237
EBritt@cvs.com

Logo - http://photos.prnewswire.com/prnh/20140905/143585

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cvs-health-chief-medical-officer-to-address-national-business-group-on-health-on-value-of-pharmacy-care-in-evolving-health-care-system-300046576.html

SOURCE CVS Health

Press Release
"Likes" Count
0